S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy

NCT00066612 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

NETWORK

Sponsor class

Conditions

Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter
Urethral Cancer

Interventions

DRUG: irinotecan hydrochloride

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]